Detection of gelatinolytic activity in developing basement membranes of the mouse embryo head by combining sensitive in situ zymography with immunolabeling

Histochemistry and Cell Biology

Volumn 138, Issue 4, 2012, Pages 557-571

  Gkantidis, Nikolaos ^a   Katsaros, Christos ^a   Chiquet, Matthias ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Basement membrane; Craniofacial development; Dye quenched gelatin; Immunofluorescence; In situ zymography; Matrix metalloproteinase; Mouse embryo

Indexed keywords

COLLAGENASE 3; GELATIN; GELATINASE; GELATINASE A; GELATINASE B; LAMININ; MATRIX METALLOPROTEINASE 14; SCLEROPROTEIN;

ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; EMBRYO; FLUORESCENCE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MANDIBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ZYMOGRAPHY;

ANIMALS; BASEMENT MEMBRANE; EMBRYO RESEARCH; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING;

MAMMALIA;

EID: 84867331408     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-012-0982-8     Document Type: Article

References (59)

1. Abiko Y, Kutsuzawa M, Kowashi Y, Kaku T, Tachikawa T (1999) In situ detection of gelatinolytic activity in developing craniofacial tissues. Anat Embryol (Berl) 200:283-287
2. Aiken A, Khokha R (2010) Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice. Biochim Biophys Acta 1803:121-132
3. Al Aqeel A, Al Sewairi W, Edress B, Gorlin RJ, Desnick RJ, Martignetti JA (2000) Inherited multicentric osteolysis with arthritis: a variant resembling Torg syndrome in a Saudi family. Am J Med Genet 93:11-18
4. Aufderheide E, Ekblom P (1988) Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions. J Cell Biol 107:2341-2349
5. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727
6. Blavier L, Lazaryev A, Groffen J, Heisterkamp N, DeClerck YA, Kaartinen V (2001) TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Mol Biol Cell 12:1457-1466
7. Bruni-Cardoso A, Lynch CC, Rosa-Ribeiro R, Matrisian LM, Carvalho HF (2010) MMP-2 contributes to the development of the mouse ventral prostate by impacting epithelial growth and morphogenesis. Dev Dyn 239:2386-2392
8. Butler GS, Overall CM (2009) Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 48:10830-10845
9. Chin JR, Werb Z (1997) Matrix metalloproteinases regulate morphogenesis, migration and remodeling of epithelium, tongue skeletal muscle and cartilage in the mandibular arch. Development 124:1519-1530
10. Chiquet M, Eppenberger HM, Turner DC (1981) Muscle morphogenesis: evidence for an organizing function of exogenous fibronectin. Dev Biol 88:220-235
11. Clark IM, Young DA, Rowan AD (2010) Matrix metalloproteinase protocols. Humana Press, New York
12. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9-34
13. Egeblad M, Shen HC, Behonick DJ, Wilmes L, Eichten A, Korets LV, Kheradmand F, Werb Z, Coussens LM (2007) Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn 236:1683-1693
14. Ehrismann R, Chiquet M, Turner DC (1981) Mode of action of fibronectin in promoting chicken myoblast attachment. Mr = 60,000 gelatin-binding fragment binds native fibronectin. J Biol Chem 256:4056-4062
15. Evans RD, Itoh Y (2007) Analyses of MT1-MMP activity in cells. Methods Mol Med 135:239-249
16. Frederiks WM, Mook OR (2004) Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases: review and protocols. J Histochem Cytochem 52:711-722
17. Galis ZS, Sukhova GK, Libby P (1995) Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 9:974-980
18. Hibbs MS, Hoidal JR, Kang AH (1987) Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J Clin Invest 80:1644-1650
19. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H (1999) MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81-92
20. Iamaroon A, Wallon UM, Overall CM, Diewert VM (1996) Expression of 72-kDa gelatinase (matrix metalloproteinase-2) in the developing mouse craniofacial complex. Arch Oral Biol 41:1109-1119
21. Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, Nemori R, Yoshioka T (2000) Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res 6:3290-3296
22. Knauper V, Cowell S, Smith B, Lopez-Otin C, O'Shea M, Morris H, Zardi L, Murphy G (1997) The role of the C-Terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272:7608-7616
23. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V (2000) Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148:615-624
24. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H (2007) Substrate choice of membrane-Type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci 98:563-568
25. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685
26. Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell HW, Foidart JM, Noel A, Rakic JM (2003) MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J 17:2290-2292
27. Lombardi F, Fasciglione GF, D'Apice MR, Vielle A, D'Adamo M, Sbraccia P, Marini S, Borgiani P, Coletta M, Novelli G (2008) Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome. Clin Genet 74:374-383
28. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ (2001) Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet 28:261-265
29. Merkle M, Ribeiro A, Sauter M, Ladurner R, Mussack T, Sitter T, Wornle M (2010) Effect of activation of viral receptors on the gelatinases MMP-2 and MMP-9 in human mesothelial cells. Matrix Biol 29:202-208
30. Miettinen PJ, Chin JR, Shum L, Slavkin HC, Shuler CF, Derynck R, Werb Z (1999) Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat Genet 22:69-73
31. Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, Majeska RJ, Schaffler MB, Martignetti JA (2007) Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 16:1113-1123
32. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-564
33. Mungall BA, Pollitt CC, Collins R (1998) Localisation of gelatinase activity in epidermal hoof lamellae by in situ zymography. Histochem Cell Biol 110:535-540
34. Nagel H, Laskawi R, Wahlers A, Hemmerlein B (2004) Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 44:222-231
35. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149
36. Nishida Y, Miyamori H, Thompson EW, Takino T, Endo Y, Sato H (2008) Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for ProMMP-2 generates active MMP-2. Cancer Res 68:9096-9104
37. Odaka C, Tanioka M, Itoh T (2005) Matrix metalloproteinase-9 in macrophages induces thymic neovascularization following thymocyte apoptosis. J Immunol 174:846-853
38. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW (1999) Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464-8475
39. Overall CM (2002) Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 22:51-86
40. Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629
41. Paulsson M, Aumailley M, Deutzmann R, Timpl R, Beck K, Engel J (1987) Laminin-nidogen complex. Extraction with chelating agents and structural characterization. Eur J Biochem 166:11-19
42. Porto IM, Rocha LB, Rossi MA, Gerlach RF (2009) In situ zymography and immunolabeling in fixed and decalcified craniofacial tissues. J Histochem Cytochem 57:615-622
43. Robbins JR, McGuire PG, Wehrle-Haller B, Rogers SL (1999) Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. Dev Biol 212:255-263
44. Sakakura Y, Hosokawa Y, Tsuruga E, Irie K, Yajima T (2007) In situ localization of gelatinolytic activity during development and resorption of Meckel's cartilage in mice. Eur J Oral Sci 115:212-223
45. Sakuraba I, Hatakeyama J, Hatakeyama Y, Takahashi I, Mayanagi H, Sasano Y (2006) The MMP activity in developing rat molar roots and incisors demonstrated by in situ zymography. J Mol Histol 37:87-93
46. Shi J, Son MY, Yamada S, Szabova L, Kahan S, Chrysovergis K, Wolf L, Surmak A, Holmbeck K (2008) Membrane-Type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol 313:196-209
47. Snoek-van Beurden PA, Von den Hoff JW (2005) Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38:73-83
48. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z (2004) Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 131:5883-5895
49. Trachslin J, Koch M, Chiquet M (1999) Rapid and reversible regulation of collagen XII expression by changes in tensile stress. Exp Cell Res 247:320-328
50. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
51. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422
52. Wang J, Tsirka SE (2005) Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128:1622-1633
53. Wehrle B, Chiquet M (1990) Tenascin is accumulated along developing peripheral nerves and allows neurite outgrowth in vitro. Development 110:401-415
54. Woessner JF Jr (1995) Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248:510-528
55. Xu X, Wang Y, Lauer-Fields JL, Fields GB, Steffensen B (2004) Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol 23:171-181
56. Yan SJ, Blomme EA (2003) In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections. Vet Pathol 40:227-236
57. Zamilpa R, Lopez EF, Chiao YA, Dai Q, Escobar GP, Hakala K, Weintraub ST, Lindsey ML (2010) Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 10:2214-2223
58. Zankl A, Pachman L, Poznanski A, Bonafe L, Wang F, Shusterman Y, Fishman DA, Superti-Furga A (2007) Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. J Bone Miner Res 22:329-333
59. Zhang HQ, Chang M, Hansen CN, Basso DM, Noble-Haeusslein LJ (2011) Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 8:206-220